DDInter1082 DDInter1741
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is a myeloid malignancy in the dendritic cell lineage. It was also approved by the European Commission on January 7, 2021.
Tagraxofusp {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tagraxofusp {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Tagraxofusp {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Tagraxofusp may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tagraxofusp may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Tagraxofusp may lead to a major life threatening interaction when taken with Mipomersen